dc.contributor.author | Üstüner, Pelin | |
dc.contributor.author | Balevi, Ali | |
dc.contributor.author | Özdemir, Mustafa | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:57:58Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:57:58Z | |
dc.date.issued | 2017 | en_US |
dc.identifier.citation | Üstüner, P., Balevi, E. ve Özdemir, M. (2017). Best dilution of the best corticosteroid for intralesional injection in the treatment of localized alopecia areata in adults. Journal of Dermatological Treatment, 28(8), 753-761. https://dx.doi.org/10.1080/09546634.2017.1329497 | en_US |
dc.identifier.issn | 0954-6634 | |
dc.identifier.issn | 1471-1753 | |
dc.identifier.uri | https://dx.doi.org/10.1080/09546634.2017.1329497 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/3084 | |
dc.description | WOS: 000416888400013 | en_US |
dc.description | PubMed ID: 28489468 | en_US |
dc.description.abstract | Purpose: To evaluate and compare the clinical efficacy, dermoscopic results and safety of triamcinolone acetonide (TA) and betamethasone dipropionate (BD) injections at different concentrations in localized scalp and beard alopecia. Methods: Intralesional injection of BD or TA in three different dilutions; 1/4, 1/8, 1/12 (BD1, BD2, BD3, TA1, TA2, TA3) and Saline (control) was randomly applied to a total of 231 alopecia patches in 83 patients every four weeks in a maximum of six sessions until a hair regrowth score of 4 was achieved. The number of required sessions, sixth-month hair regrowth scores, treatment success rates and dermoscopic data were investigated. Results: The mean number of required sessions were similar and significantly lower in BD1 and TA1 being 4.21 +/- 1.12 and 3.74 +/- 0.99, respectively. Dermoscopic examinations revealed similar terminal hair growth rations in Saline (30.3%), BD1 (44.4%) and TA1 (42.9%). However, sixth-month hair regrowth scores, overall treatment success rates and percentage of terminal hair regrowth were similar in BD1 and TA1. However, adverse effects were more common in TA groups (24.3%) than in BD groups (10.6%) at the sixth month. Conclusions: BD 1= 4 dilution (1.25 mg/dL) seems best corticosteroid for intralesional injection in the treatment of localized alopecia areata in adults. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Taylor & Francis Ltd. | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Alopecia | en_US |
dc.subject | Alopecia Areata | en_US |
dc.subject | Betamethasone Dipropionate | en_US |
dc.subject | Injections | en_US |
dc.subject | Intralesional | en_US |
dc.subject | Triamcinolone Acetonide | en_US |
dc.title | Best dilution of the best corticosteroid for intralesional injection in the treatment of localized alopecia areata in adults | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Dermatological Treatment | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıklar Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-7885-0537 | en_US |
dc.authorid | 0000-0001-5057-0405 | en_US |
dc.authorid | 0000-0002-7022-913X | en_US |
dc.identifier.volume | 28 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.startpage | 753 | en_US |
dc.identifier.endpage | 761 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1080/09546634.2017.1329497 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.scopusquality | Q1 | en_US |